We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-13.71%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$96.9M
AUM Growth
-$65.3M
Cap. Flow
-$15.2M
Cap. Flow %
-15.65%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$8.91M

Sector Composition

Rank Sector Weight
1 Miscellaneous 74.78%
2 Healthcare 25.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$12M 12.33%
875,000
– –
YARW
2
Yarrow Bioscience
YARW
$98.8M
$11.9M 12.24%
406
– –
NBRV
3
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$619K 0.64%
712
-7,780
-92% -$8.91M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q2 2018 Portfolio in Review

As of Q2 2018, venBio Partners held 4 positions worth $96.9M, down 40% from $162M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $15.2M in Q2 2018, reducing 2 holdings. Its largest reduction was Nabriva Therapeutics plc Ordinary Shares Ireland, cutting an estimated $8.91M.

By sector, the portfolio is most concentrated in Miscellaneous at 75% of assets, up from 49% a quarter earlier, followed by Healthcare.

  • venBio Partners's biggest Q2 2018 reduction was Nabriva Therapeutics plc Ordinary Shares Ireland, cutting an estimated $8.91M.
  • venBio Partners's ten largest holdings make up 100% of its $96.9M portfolio in Q2 2018.
  • venBio Partners opened 0 new positions and closed 0 in Q2 2018.
  • venBio Partners's portfolio value fell 40% quarter-over-quarter to $96.9M.

Based on venBio Partners's 13F filing for Q2 2018, filed 14 Aug 2018.